# 213 ‒ Liquid biopsies and cancer detection | Max Diehn, M.D. Ph.D.

**Channel:** Peter Attia MD
**Upload Date:** 2022-07-11
**URL:** https://www.youtube.com/watch?v=rOU3rEHlhDo
**Duration:** 146 minutes

## Description

Watch the full episode and view show notes here: https://bit.ly/3nMlzW6
Become a member to receive exclusive content: https://bit.ly/3IsZmpM
Sign up to receive Peter's email newsletter: https://bit.ly/3nMvn2o

Max Diehn is a Professor of Radiation Oncology at Stanford and a clinical radiation oncologist specializing in lung cancer. Max’s research focuses on developing novel methods for detecting circulating tumor DNA in the blood of cancer patients and on elucidating the molecular pathways and genes associated with cancer. His interests also include uncovering biomarkers that can predict patient survival, responses to therapy, and disease recurrence. In this packed episode, Max discusses the history of blood-based cancer screening and the importance of understanding the predictive value of tests—sensitivity, specificity, negative predictive value, positive predictive value – and how these metrics play into cancer screening. Max then goes in depth on the topic of liquid biopsies, including the history, current landscape, and possible future of liquid biopsies as a cancer detection tool. He discusses how these non-invasive blood tests can detect DNA/RNA from tumor cells released into the blood as well as the different methods one can use to predict if a cancer is present. He gets granular on the topic of cell-free DNA/RNA signature, methylation patterns, and the importance of knowing mutation information, and he ends with a discussion on the exciting future of liquid biopsies and how we can possibly get to the panacea of cancer screening.

We discuss:
0:00:00 - Intro
0:00:08 - Max’s training that planted the seeds for development of liquid biopsies
0:08:45 - Max’s decision to specialize in radiation oncology
0:16:00 - A culture at Stanford that values research and physician scientists
0:18:50 - The motivation to develop liquid biopsies
0:26:47 - History of blood-based cancer screening and understanding the predictive value of tests
0:34:49 - Current state of lung cancer and the need for better screening
0:46:46 - Low-dose CT scans: an important tool for managing lung cancer but with limitations
0:53:21 - Using liquid biopsies to identify circulating tumor cells
1:12:25 - Liquid biopsy research moves from circulating tumor cells to cell-free DNA
1:21:41 - Zeroing-in on circulating tumor DNA in cell-free DNA
1:34:59 - Cell-free RNA and Max’s vision for cancer detection from a blood sample
1:37:41 - Methylation patterns and other informative signatures found in DNA
1:40:15 - Mutation-based methods of liquid biopsies
1:45:27 - Understanding the sensitivity and specificity of a diagnostic test
1:53:57 - Existing clinical liquid biopsy tests and their limitations
2:01:22 - The future of liquid biopsies
2:10:48 - How we get to the panacea of cancer screening

--------
About:

The Peter Attia Drive is a weekly, ultra-deep-dive podcast focusing on maximizing health, longevity, critical thinking…and a few other things. With over 45 million episodes downloaded, it features topics including fasting, ketosis, Alzheimer’s disease, cancer, mental health, and much more.

Peter is a physician focusing on the applied science of longevity. His practice deals extensively with nutritional interventions, exercise physiology, sleep physiology, emotional and mental health, and pharmacology to increase lifespan (delay the onset of chronic disease), while simultaneously improving healthspan (quality of life).

Learn more: https://peterattiamd.com

Connect with Peter on:
Facebook: http://bit.ly/PeterAttiaMDFB
Twitter: http://bit.ly/PeterAttiaMDTW
Instagram: http://bit.ly/PeterAttiaMDIG

Subscribe to The Drive:
Apple Podcast: http://bit.ly/TheDriveApplePodcasts
Overcast: http://bit.ly/TheDriveOvercast
Spotify: http://bit.ly/TheDriveSpotify
Google Podcasts: http://bit.ly/TheDriveGoogle

Disclaimer: This podcast is for general informational purposes only and does not constitute the practice of medicine, nursing, or other professional healthcare services, including the giving of medical advice. No doctor-patient relationship is formed. The use of this information and the materials linked to this podcast is at the user's own risk. The content on this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they have, and they should seek the assistance of their healthcare professionals for any such conditions. I take conflicts of interest very seriously. For all of my disclosures and the companies I invest in or advise, please visit my website where I keep an up-to-date and active list of such companies.

## AI Summary

Here's my comprehensive analysis of this episode:

1. **Executive Summary**:
This episode features Dr. Max Diehn discussing liquid biopsies and cancer detection. The conversation focuses on the evolution, current state, and future potential of liquid biopsy technology for cancer detection and monitoring. Key areas covered include cell-free DNA detection, circulating tumor cells, and the challenges of early cancer detection. The discussion emphasizes both the promise and limitations of current liquid biopsy technology, particularly in screening applications versus monitoring known cancers.

2. **Key Medical/Scientific Points**:
- Cell-free DNA fragments are typically 170 bases long and wrapped around histones [01:12:30]
- Current liquid biopsy sensitivity for stage 1 lung cancer is around 5% [01:45:00]
- Mutation-based detection methods can achieve sensitivity of one part in a million [01:32:00]
- Most cell-free DNA (80-90%) comes from white blood cells [01:52:00]
- Cancer-derived cell-free DNA fragments are slightly shorter than normal cell-free DNA [01:52:30]

3. **Health Optimization Tips**:
Universal recommendations:
- Regular cancer screening is still important as liquid biopsies are not yet reliable enough for general screening [01:40:00]
- Consider liquid biopsies as complementary to, not replacement for, traditional screening methods [01:55:00]

4. **Biomarkers & Testing**:
- Cell-free DNA levels in healthy individuals: 1-5 nanograms per ml [01:15:00]
- Advanced cancer patients may show hundreds of nanograms per ml [01:15:30]
- Current FDA-approved liquid biopsies:
  - Guardant Health
  - Foundation One
  - Cell Search
  - Others [02:00:00]

5. **Notable Quotes**:
"The sensitivity of the methylation-based approaches is significantly inferior to that of the mutation-based approaches" [01:35:00]

"Even though they're exciting technologies and we're very hopeful that they will [work], we shouldn't just give them a pass because they're high-tech and not do the right clinical science" [02:24:00]

6. **Follow-up Questions**:
1. What is the potential for combining multiple detection methods (methylation, mutation, fragmentomics) to improve sensitivity?
2. How might liquid biopsies be integrated with AI/machine learning for improved accuracy?
3. What role might liquid biopsies play in monitoring treatment response?

This analysis captures the main points while maintaining the timestamps for reference. Would you like me to expand on any particular section?
